Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S ...Middle East

PR Newswire - News
Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S
BEIJING and SHANGHAI and BOSTON, Jan. 8, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completed the first patient dosage of its in-house R&D drug candidate Aurora A Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S. JAB-2485 is...

Hence then, the article about jacobio completes first patient dosage of aurora a inhibitor jab 2485 in u s was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News